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Abstract
Elevated blood pressure (BP), a leading cause of global morbidity and mortality, is influenced by both genetic and lifestyle
factors. Cigarette smoking is one such lifestyle factor. Across five ancestries, we performed a genome-wide gene–smoking
interaction study of mean arterial pressure (MAP) and pulse pressure (PP) in 129 913 individuals in stage 1 and follow-up
analysis in 480 178 additional individuals in stage 2. We report here 136 loci significantly associated with MAP and/or PP. Of
these, 61 were previously published through main-effect analysis of BP traits, 37 were recently reported by us for systolic BP
and/or diastolic BP through gene–smoking interaction analysis and 38 were newly identified (P<5×10−8, false discovery
rate<0.05). We also identified nine new signals near known loci. Of the 136 loci, 8 showed significant interaction with
smoking status. They include CSMD1 previously reported for insulin resistance and BP in the spontaneously hypertensive
rats. Many of the 38 new loci show biologic plausibility for a role in BP regulation. SLC26A7 encodes a chloride/bicarbonate
exchanger expressed in the renal outer medullary collecting duct. AVPR1A is widely expressed, including in vascular smooth
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muscle cells, kidney, myocardium and brain. FHAD1 is a long non-coding RNA overexpressed in heart failure. TMEM51 was
associated with contractile function in cardiomyocytes. CASP9 plays a central role in cardiomyocyte apoptosis. Identified
only in African ancestry were 30 novel loci. Our findings highlight the value of multi-ancestry investigations, particularly in
studies of interaction with lifestyle factors, where genomic and lifestyle differences may contribute to novel findings.
Introduction
Elevated blood pressure (BP), a leading cause of morbidity and
mortality worldwide, is known to be influenced by both genetic
and lifestyle factors. To date genome-wide association studies
(GWAS) have identified over 1000 loci associated with BP and
hypertension (1–10). The effects of genetic variants on BP may
manifest differently depending on lifestyle exposures. There-
fore, incorporating gene–environment (G×E) interactions may
identify additional loci (11,12).We established the Gene–Lifestyle
Interactions Working Group within the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) Consor-
tium in order to assess the impact of interactions with multiple
lifestyle factors on the genetics of cardiovascular traits (13).
Among many lifestyle factors, cigarette smoking influences BP
in both acute (14) and chronic (15) fashion, motivating genetic
association studies of gene-by-smoking interactions.
Recently we reported findings from a genome-wide associa-
tion meta-analysis incorporating gene–smoking interactions for
systolic BP (SBP) and diastolic BP (DBP) (16). In addition to SBP
and DBP, BP can also be characterized as having both steady and
pulsatile components, each determined by different physiologic
properties of the heart and vasculature and differently related to
cardiovascular outcomes. Mean arterial pressure (MAP) reflects
the steady component of BP,which is predominantly determined
by cardiac output and systemic vascular resistance and regu-
lated by small artery and arteriole tone (17).MAP has been found
to be more ‘informative’ than SBP and DBP in predicting mortal-
ity from cardiovascular disease including stroke and ischemic
heart disease (18,19). Pulse pressure (PP) represents the pulsatile
component of BP and is largely determined by cardiac stroke
volume and large artery stiffness (17,20). PP has been found to
be predictive of coronary heart disease risk and, in some cases,
superior to both SBP andDBP, in particular for older adults (21,22).
Thus,while SBP is prioritized as the primary treatment target for
hypertension (23), MAP and PP continue to be relevant BP traits
for investigation. Understanding their biological underpinnings
may lead to discovery of new BP pathways.
In this study,we performed a genome-wide associationmeta-
analysis ofMAP and PP incorporating gene–smoking interactions
(Fig. 1). The aim is to evaluate whether any of the previously
identified BP loci are modified by smoking, whether interactions
can be identified using a genome-wide approach and whether
additional novel BP loci can be identified by accounting for
potential single nucleotide polymorphism (SNP)–smoking inter-
actions.Here,we report our findings through two degrees of free-
dom (DF) test that jointly evaluates genetic main and interaction
effects (24) based on 610091 individuals across five ancestries.
Results
Overview
Across five ancestries, we performed a genome-wide gene–
smoking interaction study of MAP and PP in 129913 individuals
in stage 1 and follow-up analysis in 480 178 additional indi-
viduals in stage 2: summary information is in Table 1 (Supple-
mentary Materials, Tables S1–S6). Through genome-wide search
in stage 1, we identified 1692 significant (P≤ 5×10−8) and 2681
suggestive (P≤10−6) variants associated with MAP and/or PP.
Figure 1. Study design. Summary of data included in this study. Smk: smoking status (considering either current smoking or ever smoking status separately); PC:
principal component; EUR: European; AFR: African; ASN: Asian; HIS: Hispanic; BRZ: Brazilian; TRANS; trans-ancestry (i.e. combining all ancestry groups through meta-
analysis).
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Table 1. Basic characteristics of cohorts in stages 1 and 2 in each ancestry
Current
smoker
Former
smoker
Never smoker Male HTN HT meds Age MAP PP
N % N % N % % % % Mean SD Mean SD Mean SD
Stage 1
EUR 14607 18.1 28 409 35.3 37 535 46.6 32.6 38.2 25.4 54.63 8 94.63 12.9 52.02 13.3
AFR 5545 21.5 7185 27.8 13 121 50.8 26.5 55.9 39.5 54.49 9.1 99.96 14.9 54.67 16.4
ASN 2465 18.3 1677 12.5 9296 69.2 51.2 46.9 27 55.42 9.7 98.70 13.4 57.86 15.8
HIS 1068 12.1 2160 24.5 5577 63.3 24.9 43.5 13.3 55.5 11 94.80 13.9 53.55 16.4
Stage 1 total 23 685 18.4 39 431 30.7 65 529 50.9 32.8 43.1 27.7 54.74 8.6 96.17 13.4 53.28 14.4
Stage 2
EUR 48198 17 89597 31.6 145914 51.4 47.8 44.8 25 55.91 8.6 102.17 13.5 55.29 13.9
AFR 1971 29.8 1579 23.8 3075 46.4 40.9 54.3 42.8 53.66 10.2 101.21 14.7 53.68 14.8
ASN 29485 19.8 40 850 27.4 78 597 52.8 54.9 50.3 33.1 60.76 12.3 98.31 13.9 54.91 14.0
HIS 2739 20.3 2559 18.9 8231 60.8 41 26.9 16.3 45.86 13.8 91.36 13.7 48.99 13.3
BRZ 998 22.6 514 11.6 2902 65.8 48 15.5 6.3 27.78 3.2 89.75 12.3 45.23 9.8
Stage 2 total 83 391 18.2 135 099 29.6 238719 52.2 49.7 45.9 27.4 56.84 9.9 100.54 13.7 54.88 13.9
TOTAL 107076 18.3 174530 29.8 304248 51.9 46.1 45.3 27.4 56.4 9.6 99.61 13.6 54.54 14.0
The cell entries for the covariates and BP traits correspond to sample-size-weighted averages across all cohorts in each category. EUR: European; AFR: African; ASN:
Asian; HIS: Hispanic; BRZ: Brazilian; ALL: trans-ancestry (i.e. combining all ancestry groups through meta-analysis); HTN: hypertension; MAP: mean arterial pressure;
PP: pulse pressure.
Of these 4373 variants, 2982 variants were replicated in stage
2 with P<0.05/4373 (to an aggregate replication rate of 68.2%).
Of the 1692 significant variants in stage 1, a total of 1449 were
replicated in stage 2 with P<0.05/1692 to a replication rate of
85.6%. Among the genome-wide significant variants in stage 1,
which resided in 112 loci (defined by physical distance ± 1 Mb),
53 loci were formally replicated in stage 2 using Bonferroni-
adjusted significance levels (P<0.05/112). Most of the remaining
59 loci were identified in African or Hispanic ancestries in stage
1, which quite plausibly failed to replicate in stage 2 due to
these smaller sample sizes and hence lack of power. For 10 loci,
no additional data were available in stage 2, and therefore, it
was not possible to check for replication. All of these formally
replicated loci had been identified previously: 44 through main
effects GWAS (1–8) and 9 through gene–smoking interaction
analysiswe reported recently for SBP andDBP (16). For these nine
formally replicated loci, estimates of the genetic main effects
were all consistent between stages 1 and 2; estimates of SNP-
smoking interaction effects were not statistically significant
(Supplementary Material, Table S7).
We performedmeta-analysis combining stages 1 and 2 (Man-
hattan plots, Supplementary Material, Fig. S1; quantile–quantile,
QQ, plots, Supplementary Material, Fig. S2). Through this com-
bined analysis with 610091 individuals, we identified 136 loci
that were associated with MAP and/or PP at genome-wide sig-
nificance (P≤5× 10−8). Of these, 61 loci were previously pub-
lished through main effects GWAS for any BP trait (1–8), 37 loci
(presented in Supplementary Material, Table S7) were recently
reported by us for SBP and/or DBP through gene–smoking inter-
action analysis (16) and the remaining 38 loci are newly reported
here (Table 2).
Among the 136 loci associated with MAP and/or PP, 38 loci
are completely new and at least 1 Mb away from any of known
BP loci. A total of 16 novel loci passed a more stringent thresh-
old (P<6.25× 10−9, adjusted for two smoking exposures, two
tests and two BP traits). We also identified nine additional new
signals within the known BP loci but not in linkage disequilib-
rium (LD), r2 <0.1, with known BP loci (Table 3). Among the nine
identified signals, four signals were identified in trans-ancestry,
and the remaining five were ancestry-specific (two European,
two African and one Hispanic signals). The LocusZoom plots
for these completely novel 38 loci and 9 signals are shown in
Supplementary Material, Figure S3. As shown in Venn diagram
(Fig. 2), among 38 new loci and 9 signals, 38 were newly PP
associated and 12 were newly MAP associated (with 3 common
between PP and MAP). These were not associated with SBP
or DBP. False discovery rate (FDR) q-values provided additional
evidence for these newly identified loci (FDR<0.01 for 43 of the
47 and FDR<0.05 for all 47 loci or signals).
Supplementary Material, Table S8 presents more detailed
results for the lead variants representing the 136 loci and the
9 signals associated with MAP and PP: ancestry-specific and
trans-ancestry meta-analysis results within each stage (1 and 2)
and ancestry-specific and trans-ancestry meta-analysis results
combining stages 1 and 2. Scatterplots comparing ancestry-
specific genetic effects at these variants are presented in
Supplementary Material, Figure S4. Genetic effects between
European and Hispanic ancestries had the highest correlation
(0.79), whereas those between African and Hispanic ancestries
had the lowest correlation (0.29).
The role of interactions
Among the 136 loci and 9 new signals associated with MAP
and/or PP, variants at 8 loci showed genome-wide significant
interactions (1 DF interaction P<5×10-8) with smoking status
(Fig. 3).All eight loci were identifiedwith current smoking status;
these variants have larger effects in current smokers than in
non-current smokers. Of the eight loci, six loci showed increas-
ing effects on BP in current-smokers. Five interactions were
newly identified (Table 2), and the other three were previously
reported for SBP or DBP (Supplementary Material, Table S7).
These variants showing interaction effects were identified only
in individuals of African ancestry in stage 1. These variants
were not present in stage 2 because of the limited sample size
(ranges from 418 to 1993) of stage 2 African ancestry cohorts,
and therefore, replication of these interactions was not possible.
BP variance explained
Within each of the smoking strata, we computed the variance of
MAP and PP explained by genome-wide results (25) in European
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Table 3. Nine new signals associated with MAP and/or PP that are near known BP loci (but not in LD, r2 <0.1)
Locus rsID Nearest gene Position EAF Race Trait/
exposure
G
effect
G
StdErr
G×E
effect
G×E
StdErr
Interaction
P
Joint P FDR q
value
1 rs140881076 KAZN 1:15364113 0.01 AFR PP/CS 0.45 1.13 −11.95 1.85 2.30E-03 3.29E-14∗ 4.16E-10
2 rs2071405 AGT 1:230850658 0.13 Trans MAP/CS 0.28 0.04 −0.18 0.09 0.20 3.02E-12∗ 1.62E-08
3 rs143802076 C3orf38 3:88646080 0.01 AFR PP/CS −0.50 0.90 −8.54 1.68 8.97E-04 1.33E-09∗ 9.81E-06
4 rs1009382 TNXB 6:32026107 0.71 EUR PP/CS 0.26 0.04 −0.16 0.08 0.15 4.84E-13∗ 3.30E-09
5 rs7005363 MSRA 8:10283748 0.54 EUR MAP/ES −0.34 0.04 0.15 0.06 0.02 3.13E-17∗ 1.59E-13
6 rs187148391 TXN 9:112998518 0.99 HIS MAP/ES 0.09 0.69 4.48 1.03 1.01E-03 1.95E-08 0.013302
7 rs10894198 ADAMTS8 11:130285493 0.38 Trans PP/CS 0.27 0.03 −0.12 0.07 0.33 1.38E-19∗ 3.19E-15
8 rs1010064 LOC100506393
PDE3A
12:20000315 0.75 Trans MAP/ES 0.24 0.04 −0.12 0.06 0.03 5.91E-11∗ 6.64E-10
9 rs201028933 LOC338758 12:90111249 0.79 Trans MAP/ES 0.32 0.08 0.16 0.11 0.28 1.73E-11∗ 9.75E-08
A new signal is defined as a significantly associated variant within 1 Mb of known BP loci but in weak LD r2 < 0.1 with the known BP loci. LD for the trans-ancestry
signals was based on the entire 1000 Genomes cosmopolitan data, whereas LD for ancestry-specific signals was based on ancestry-specific population (e.g. LD for
European signals were based on 1000 Genomes European data). Each locus is genome-wide significant (P< 5×10-8) in the combined analyses of stages 1 and 2 and had
FDR q value< 0.05. Positions are based on human genome build 37. EA: effect allele; EAF: effect allele frequency; G effect: the estimate of the genetic main effect
(
βG
)
;
G×E effect: the estimate of genetic–smoking interaction effect
(
βGE
)
; Interaction P: P-value for testing the G×E interaction effect with one DF; Joint P: P-value for jointly
testing Gmain and G×E interaction effects with two DF; EUR: European ancestry. Trans: trans-ancestry (i.e. combining all ancestry groups throughmeta-analysis); MAP:
mean arterial pressure; PP: pulse pressure; CS: current-smoking; ES: ever-smoking.
∗Findings with an asterisk indicate statistical significance using a stricter P-value threshold, after Bonferroni correction for two smoking traits, two tests, and two BP
traits (5× 10−8/8= 6.25×10−9).
Figure 2. Venn diagram of loci/signals associated with the four BP traits. The diagram shows 133 loci and/or signals that were identified through gene–smoking
interactions. In this paper, we newly identified 38 loci (Table 2) and 9 signals near known BP loci (Table 3) that are unique to MAP and/or PP (to a total of 49 new
loci/signals). We had reported 81 loci associated with SBP/DBP (16), among which 37 showed association with MAP or PP. SBP: systolic blood pressure; DBP, diastolic
blood pressure; MAP: mean arterial pressure; PP: pulse pressure.
ancestry (Fig. 4). The independent set of variants, 38 for MAP
and 12 for PP, with P≤5×10-8 explained 1.9% of variance in MAP
and 0.5% of variance in PP. The difference in explained variance
between the smokers and non-smokers was not significant,
suggesting that BP variance explained by interaction effects is
very small. Similar inference was observed with the results from
ever-smoking status (data not shown).
Functional inferences
To obtain functional annotations fromHaploReg (26),we focused
on the index variants representing the 84 loci (38 novel loci,
9 new signals near known loci and 37 recently reported) that
showed associationwithMAP and/or PP.Therewas onemissense
variant, rs1009382. Of the remaining non-coding variants (37
intronic and 51 intergenic), 15 were in promoter histone marks,
47 in enhancer histone marks, 28 in DNase I marks and 8 altered
the binding sites of regulatory proteins (SupplementaryMaterial,
Table S9). Using GERP (27), five variants were identified as being
conserved among vertebrates, with three variants identified as
such using SiPhy (28). For 27 variants, cis-expression quantitative
trait loci (eQTL) evidence was available with varying degrees of
association with expression probes. In particular, 10 of them
were identified by GTEx (29) as cis-eQTLs across various tissues
(Supplementary Material, Table S9). In addition, we obtained
information onmicroarray-based gene and exon expression lev-
els inwhole blood from over 5000 individuals of the Framingham
Heart Study (30) (SupplementaryMaterial, Table S10). Therewere
109 variant-transcript pairs (representing 26 variants) with cis-
eQTL evidence (at P<8.9× 10-5, FDR<0.002). Among 26 variants
(Supplementary Material, Table S10), the 3 variants had the
most abundant evidence of cis-eQTL association: rs112947839,
rs1009382 and rs7753826 associated with 21, 18, and 10 tran-
scripts, respectively.
The analyses using data-driven expression prioritized inte-
gration for complex traits (DEPICT) prioritized genes (FDR<5%)
at 40 loci, including 16 genes that did notmatch the nearest gene
of the identified lead variant (Supplementary Material, Table S11).
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Figure 3. Smoking-specific genetic effect sizes in African ancestry for MAP or PP. Among the 138 loci significantly associated with MAP and/or PP, 8 loci show significant
interactions with smoking exposure status in African ancestry. Smoking-specific effect estimates and 95% confidence intervals for variants associated with BP traits
are shown as red and blue squares for current-smokers and non-current smokers, respectively. SNP effects between two strata are significantly different (one DF
interaction P< 5×10−8). These results were based on African-specific results in stage 1. MAP: mean arterial pressure; PP: pulse pressure; CS: current-smoking.
Figure 4. Smoking-specific estimates of variance explained in European ancestry. The variants with P≤ 5×10-8 explained 1.9% of variance in MAP and 0.5% of variance
in PP, whereas variants with P≤ 10-4 explained 16% of variance in MAP and 11% of variance in PP. The vertical line corresponds to FDR= 0.1.
Furthermore, the analyses highlighted 56 significantly (FDR<5%)
enriched gene sets. Many of these highlight cardiovascular
mechanisms, such as ‘abnormal blood vessel morphology’, ‘thin
myocardium’ or ‘abnormal heart development’ (Supplementary
Material, Table S12). We also observed that genome-wide
significant MAP and PP loci are enriched for genes expressed
in the ileum (Supplementary Material, Table S13).
Associations of BP loci with cardiometabolic traits
We obtained association results of the 84 index variants associ-
ated with MAP or PP (representing 38 novel loci, 9 new signals
near known loci and 37 recently reported loci) with multiple
cardiometabolic traits: coronary artery disease (CAD), stroke,
adiposity, diabetes and renal function (Supplementary Materi-
als, Tables S14–S19). For 36 out of 47 scenarios (highlighted in
red, Supplementary Material, Table S20), the observed number
of variants with nominal evidence of association (P <0.05) was
higher than that expected by chance alone (PBinomial <0.05/11,
corrected for 11 traits used in the lookups). For example, we
observed 7 and 11 such associations with CAD and myocardial
infarction, respectively, where the expected count is 2.2 for both
traits. Corroborating evidence of the multiple cardiometabolic
traits were found for the 2 of the 38 new loci: (rs146622638,
GPM6A; rs12156238, FAM167A) and the 5 of the 9 new signals
near known BP loci (rs2071405,AGT; rs1009382, TNXB; rs7005363,
MSRA; rs1010064, LOC100506393; rs201028933, LOC338758). These
overlapping signals support that these traits may share a com-
mon pathophysiology.
Loci overlapping with previously reported SBP or DBP
loci
Among the loci that were reported by us recently as significantly
associated with SBP and/or DBP based on gene-by-smoking
interaction analysis (16), 37 loci were also associated with MAP
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and/or PP (Supplementary Material, Table S7). Among them,
nine loci were formally replicated in stage 2 and showed
associationwith all four BP traits.Variants at these nine loci were
all also genome-wide significant in the combined analysis of
stages 1 and 2 in individuals of European ancestry. For variants at
six of the nine loci, there was supporting evidence of association
in individuals of non-European ancestry, which resulted in
stronger statistical significance from trans-ancestry analysis.
One such locus was rs351364 (in WNT2B), where only trans-
ancestry analysis reached genome-wide significance in stage 1;
the direction of the genetic effect was consistent across all
ancestries (with 2DF P=2.8×10-31; Supplementary Material,
Table S7).
New signals near known BP loci
Nine new signals were identified near known BP loci (but not
in LD, r2 <0.1). One such signal was rs140881076 (chr1:15364113,
2DF P=3.3×10-14, Fig. 5A) in association with PP in individ-
uals of African ancestry. This signal is 434 kb away and in
complete linkage equilibrium with CELA2A locus (rs3820068,
chr1:15798197) that was recently identified in individuals of
European ancestry (7,8). Several nearby genes have been impli-
cated in cardiovascular traits. FHAD1 is a long non-coding RNA
overexpressed in heart failure (31), TMEM51 has been associated
with contractile function in cardiomyocytes (32) and CASP9 plays
a central role in cardiomyocyte apoptosis (33). A candidate gene
study identified a missense mutation in CASP9 as associated
with ischemic stroke in Koreans (34). Differential methylation
patterns in TMEM51have also been described in peripheral blood
leukocytes of smokers (35,36).
Through trans-ancestry analysis, we identified one locus
(rs1010064) associated with both MAP and PP (2DF P=5.9×10-11).
This is located approximately 500 kb upstream of, but not in
LD with, PDE3A, a known BP gene with a role in regulating
growth in vascular smooth muscle cells (4,37). Missense
mutations in PDE3A have been linked with autosomal dominant
syndrome characterized by treatment-resistant hypertension
and brachydactyly (38,39). SNPs in this locus have also shown
suggestive associations with aortic root diameter (40), resistant
hypertension (41) and SBP in a SNP–alcohol consumption
interaction analysis (42).
Biological relevance of newly identified BP loci
Several genes near the 38 novel loci show biologic plausibility
for a role in BP regulation. One such gene is CSMD1 (rs140994551,
chr8:4449086, associated with PP in individuals of African ances-
try while considering interaction with current smoking status,
2DF P=2.1× 10-11, Fig. 5B). In animal models, variants in CSMD1
were associated with both insulin resistance and BP in the
spontaneously hypertensive rats (SHRs) (43). In humans, there
was suggestive evidence of association with hypertension in
two Korean cohorts (44), with peripheral artery disease in a
Japanese population (45), with waist–hip ratio adjusted for BMI
in men (46), with insulin resistance in African Americans (47)
and with studies of addiction and related disorders (48). Another
new locus is LRRC69 (rs11991823, chr8:92188440, associated with
PP, identified through trans-ancestry analysis, 2DF P=1.3×10-15,
Fig. 5C). A copy number variant in this gene has been shown to
be weakly associated (P=0.04) with BP in a Korean population
(49). The nearby gene SLC26A7 encodes a chloride/bicarbonate
exchanger expressed specifically in the renal outer medullary
collecting duct (50). Two PP loci include genes involved in the
NFkB signaling pathway (TNFRSF11A and NFIB). This inflam-
matory pathway has been implicated in hypertension-induced
renal dysfunction in murine models (51) and with endothelial
dysfunction in overweight/obese and older humans (52). There
was suggested evidence of association of variants in TNFRSF11A
with BP traits in Chinese women (53).
A new locus near AVPR1A (rs146924684 chr12:63437286, asso-
ciated with MAP, 2DF P=5.3×10-9, Fig. 5D) also has strong bio-
logic plausibility. Vasopressin is an antidiuretic hormone and a
potent vasoconstrictor that exerts its effect through activation of
a family of receptors, including the arginine vasopressin recep-
tor subtype 1A (AVPR1A) that is widely expressed including in
vascular smooth muscle cells, kidney, myocardium and brain
(54). In glomerular macula densa cells,AVPR1A facilitates activa-
tion of the renin–angiotensin–aldosterone system and increases
expression of the aquaporin 2 water channel (55). AVPR1A stim-
ulation is also necessary for maintaining normal BP; in murine
knockout models, basal BP is significantly decreased and the
arterial baroreceptor reflex markedly impaired (56). Notably,
there are data to support a role for vasopressin not only in
the maintenance, but also in the development, of hypertension.
Vasopressin receptor 1A blockade in young, still normotensive,
SHR attenuates the later development of hypertension in adult
SHR despite withdrawal of drug therapy (57).
We identified several loci with potential relevance to the
structure and function of primary cilia, in addition to those
we reported recently (16). Three PP-associated loci were near
genes implicated with nephronophthisis, including those with
mutations linked to Bardet–Biedl Syndrome (BBS7 and MYO3A)
and with Joubert Syndrome (AHI1). Another PP-associated
locus was near NEDD4L, which encodes the E3 ubiquitin
ligase NEDD4–2 and has been shown to regulate a renal
epithelial sodium channel (ENaC/SCNN1) that is critical for
maintenance of sodium homeostasis (58). ENaC is the channel
responsible for themonogenetic disorder of BP regulation, Liddle
Syndrome. Loss of NEDD4–2 in the renal tubules results in
increased activity of the ENaC channel, resulting in salt-sensitive
hypertension (59). Candidate gene studies identified variants in
NEDD4L as associated with sodium lithium countertransport
(60), hypertension (61), treatment response to β-blockers and
diuretics in hypertensive patients (61–63).
We identified two additional loci with potential relevance
to the dopaminergic system, in addition to those we reported
recently (16). Dopamine signaling plays a key role in both
central and peripheral BP regulation (64–66).A regulatory subunit
(PPP2R2A) of the dopamine receptor 2R (D2R) was associated
with MAP. In murine renal proximal tubule cells, inhibition
of this regulatory protein leads to increased expression of
markers of renal inflammation and injury (67). A newly
identified MAP-associated locus SESN2 is also related to the
dopaminergic system; activation of the D2R has been shown
to increase the expression of SESN2, which protects the
kidney against renal oxidative stress (68). SESN2 also protects
endothelial cell lines against angiotensin II-induced endothelial
toxicity (69). Two additional loci include genes involved in
dopamine signaling: ATP13A2 (70) and ARPP21 (71). Activation
of dopamine centers of the brain has also been implicated in
drug and nicotine abuse (72).
In addition,we found a PP-associated locus near SDHB, which
encodes the mitochondrial protein succinate dehydrogenase.
Variants in this gene have been identified in individuals with
carotid body tumors and pheochromocytomas/paragangliomas,
endocrine tumors that secrete dopamine and/or norepinephrine
and can modulate BP regulation even when tumors are not
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Figure 5. LocusZoom plots for four selected loci associated with MAP and/or PP. (A) rs140881076 (chr1:15364113) was identified in an analysis of individuals of African
ancestry and is intronic to KAZN; neighboring genes have been implicated in cardiovascular traits. FHAD1 is a long non-coding RNA overexpressed in heart failure,
TMEM51 has been associated with contractile function in cardiomyocytes and CASP9 plays a central role in cardiomyocyte apoptosis. (B) rs140994551 (chr8:4449086),
intronic to CSMD1, shows interaction with current smoking in individuals of African ancestry. CSMD1 are shown to be associated with insulin resistance and BP in the
spontaneously hypertensive rats. CSMD1 is also suggestively associated with studies of addiction and related disorders. (C) rs11991823 (chr8:92188440) was associated
with PP in trans-ancestry analyses and in intronic to LRRC69. The nearby gene SLC26A7 encodes a chloride/bicarbonate exchanger expressed specifically in the renal
outer medullary collecting duct. (D) rs146924684 (chr12:63437286) was associated with MAP in individuals of African ancestry. The nearby gene AVPR1A is widely
expressed including in vascular smooth muscle cells, kidney, myocardium and brain. CurSmk: current smoking status; EverSmk: ever smoking status; MAP: mean
arterial pressure; PP: pulse pressure. The plots were created using LocusZoom (http://locuszoom.sph.umich.edu/).
clinically apparent (73,74). Variants near this locus have been
marginally associated with DBP in pre-pubertal European chil-
dren (75). Tyrosinase (with its related protein, TYRP1) catalyzes
the first rate-limiting step in pathway in the formation of L-Dopa
(76). Although variants in TYRP1 were suggestively associated
with SBP by the International Consortium for Blood Pressure (77),
we identified this locus as associated with PP at genome-wide
significance.
Discussion
MAPmeasures the steady component, which is a function of the
left ventricular contractility, heart rate, small-artery resistance
and vascular elasticity averaged over time (17). PP measures the
pulsatile component, which is a function of the left ventricular
stroke volume, large-artery stiffness, early pulse wave reflectio,
and heart rate (19). These BP traits not only differ in their
physiologic properties but are also differently related to cardio-
vascular outcomes (17,19,78,79). Our genome-wide association
meta-analysis incorporating gene–smoking interactions identi-
fied 136 loci significantly associatedwithMAP and/or PP: 61were
previously published through main-effect GWAS analysis (1–8),
37were recently reported by us for SBP and/or DBP through gene–
smoking interaction analysis (16) and 38 are newly reported here.
Our analysis also identified nine new signals near known BP loci
(but not in LD, r2 <0.1).
Among the loci significantly associated with MAP and/or PP,
eight loci showed significant interaction with smoking status
from the one DF interaction tests. At these eight loci, the joint
two DF P-values ranged from 1×10-7 to 5×10-11, indicating that
loci were identified mostly because of their interaction with
smoking status. We observed that the genetic effect at these
loci is negligible in non-smokers but larger in smokers. As such,
a drug that targets this locus with strong interactions may
achieve a greater treatment effect among smokers than non-
smokers; elevated BP may be treated in smokers using such
a drug, whereas the same drug is unlikely to be effective in
non-smokers. Alternatively, physicians may counsel patients on
specific antihypertensive drugs that they may obtain greater
treatment effect if they modify their exposure (e.g. smoking ces-
sation). While precision medicine interventions are still emerg-
ing in cardiovascular care, a consideration of interaction effects
lays an important foundation. In addition to drug targeting, a
smoking interaction can also help us to identify novel biological
mechanisms underlying BP traits.
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One such locus showing significant interactionwith smoking
status is CSMD1. While variants of this gene were previously
suggested for addiction and related disorders (48), we identified
this locus at genome-wide significance (1DF P=4.3×10−9, 2DF
P=2.1×10−11). In our study, another locus near AHR showed
weak evidence of interaction with smoking (1DF P=1.6×10−4,
2DF P=1.7×10−9 associated with MAP). Variants in AHR are
shown to interactwith variants inCYP1A1, a detoxifying enzyme,
to explain BP differences between smokers and non-smokers
(80). AHR encodes a ligand-activated transcription factor, and
AHR knock-out mice have increased MAP and ventricular hyper-
trophy/fibrosis with increased plasma levels of angiotensin II
(81). Given the evidence that environmental toxins, including
tobacco smoke, activate AHR, it is pertinent to note that AHR,
in turn, activates tyrosinase activity, the rate limiting step for L-
dopa biosynthesis (76). Activation of the AHR protein represses
T-cadherin expression, which functions as a negative growth
regulator in vascular smooth muscle cells (82,83). T-cadherin
(encoded by CDH13) has been previously identified as a BP sus-
ceptibility locus (84). Notably, while the endogenous ligand for
AHR remains uncertain (85), exogenous ligands include poly-
cyclic aromatic hydrocarbons that are found in tobacco smoke
and other environmental pollutants (86).
We found that most of MAP-associated loci were previously
associated with SBP and/or DBP. This is not surprising given
that MAP is closely related physiologically to SBP and DBP. In
contrast, analysis of PP yielded a greater number of novel signif-
icant loci that are unique to PP. Loci associated with PP may be
identifying different physiologic processes than loci associated
with MAP, SBP and DBP. For example, the steady component
of BP can be effectively targeted by β-adrenergic receptor and
calcium-channel blockers that both modulate arteriolar tone.
Angiotensin converting enzyme inhibitors, which favor remod-
eling of vascular connective tissue, may impact PP to a greater
extent (87). This is a clinically important concept since hyper-
tension is often more effectively treated by combination drug
therapy to target different physiologic pathways (23).
We identified 30 loci that were statistically significant only in
the meta-analyses of African ancestry individuals (forest plots
in Supplementary Material, Fig. S5). Due to many prior BP GWAS
discoveries,mostly based on European or Asian ancestries, iden-
tifying new BP loci in European and Asian ancestries may be
challenging. There are also more opportunities to identify lower
frequency variants in African ancestry individuals because there
are more of these variants in this genetically more diverse
population (with correspondingly smaller LD blocks, allowing
closer identification of multiple underlying causal variants). The
observed effect sizes (in African ancestry, Fig. 3) may be larger
than their true values due to winners’ curse (88). All identified
loci were in low frequency [with minor allele frequency (MAF)
ranging from 1.2% to 3.1%] but had good imputation quality
scores ranging from 0.62 to 0.95 (presented in Supplementary
Material, Fig. S5). In many of these loci, forest plots show con-
sistent association across the contributing African cohorts. Out
of 30, 23 loci were only present in African ancestry, and there-
fore, these associations could not be effectively evaluated in
other ancestry groups as a result of their inter-ancestry dif-
ferences in MAF. Because of the limited sample sizes avail-
able for African ancestry in stage 2, genome-wide significant
loci in stage 1 African ancestry could not be formally repli-
cated in stage 2; only the largest African cohort in stage 2
(Health and Retirement Study, N=1993) provided association
results for a subset of 23 loci (Supplementary Material, Fig. S5).
For the remaining seven loci, we found evidence of association
in African ancestry but not in meta-analyses in other ances-
tries, despite comparable or higher allele frequencies, such as
those observed with rs11587661 (COG2) or rs72723039 (IRX2). We
found similar smoking-specific effects on lipid traits that were
unique to African ancestry (89). They may relate at least in part
to inter-ancestry differences, including preference of menthol
cigarettes. Therefore, African-specific loci should be treated cau-
tiously since they require further validation.
This large-scale multi-ancestry study has some limitations.
First, because most of the known BP loci were identified in
European and Asian ancestries, considerable effort was made to
recruit most of the available studies from the other ancestries
into stage 1. Although we were able to identify several new loci
in African ancestry, the relatively smaller stage 2 sample size
of African ancestry (N=7786) has limited our ability to replicate
these new loci. Second, some of our new loci identified through
the 2DF joint test may have been identified due to a main effect
because of a larger sample size and more diverse ancestries,
not necessarily from gene–smoking interaction. Unfortunately,
we are unable to verify this because analysis of main effects
alone, without regard to smoking status, was not performed.
Third, conditional analysis (such as genome-wide complex trait
analysis, GCTA) based on summary statistics was not performed
because valid methods do not currently exist for G×E interac-
tions. Therefore, we relied on a relatively more stringent LD
threshold (r2 <0.1) for identifying additional signals within the
know BP loci. Fourth, if there is a G×E correlation, a potential
confounding of G×E with interaction between covariate and
smoking exposure may exist. This can inflate Type I error of the
G×E interaction test (90).
In summary, this study identified 38 new loci and 9 new
signals near known BP loci that are uniquely associated with
MAP and/or PP (and not associated with SBP or DBP), demon-
strating the promise of gene–lifestyle interactions for genetic
and environmental dissection of BP traits. Of our 38 loci, 10 were
within 1Mb of those recently reported by both Evangelou et al. (9)
and Giri et al. (10); 6 loci were African-specific. Additional seven
loci (including four African-specific loci) were within 1 Mb of
those reported by Evangelou et al. (9).Variants in several lociwere
identified in individuals of African ancestry, highlighting the
importance of genetic studies in diverse populations. Many of
these new loci (including CSMD1, TMEM51, SLC26A7, TNFRSF11A
andAVPR1A) show biologic plausibility for a role in BP regulation.
They include additional loci of potential relevance to the struc-
ture and function of primary cilia and the dopaminergic system.
Understanding underlying mechanisms for the newly identi-
fied loci and biological insights into the genetics of BP traits
will require further investigation. Out of 136 significant loci,
8 showed significant interaction with smoking status. Because
some interactions may be driven by other lifestyle factors that
are correlated with smoking, a follow-up study such as Tyrrell
and her colleague (91) that jointly examines multiple lifestyle
factors can shed light on further understanding of the nature
of the smoking interaction effects on BP. Our findings highlight
the value ofmulti-ancestry investigations, particularly in studies
of interaction with lifestyle factors, where genomic and lifestyle
differences may contribute to novel findings.
Materials and Methods
Participating studies
Analyses included men and women between 18 and 80 years
of age from European (EUR), African (AFR), Asian (ASN),
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Hispanic (HIS) and Brazilian (BRZ) ancestries. A total of 48
cohorts consisting of 129 913 individuals (80 552 EUR; 27 118
AFR; 13 438 ASN; 8.805 HSP; Supplementary Material, Table S1)
participated in stage 1 and performed genome-wide analyses.
Studies that included data from multiple ancestries (cohorts)
contributed multiple analyses, one for each ancestry/cohort.
For example, multi-ethinc study of atherosclerosis has four
cohorts. A total of 76 additional cohorts consisting of 480 178
individuals (305 513 EUR; 7826 AFR; 148 932 ASN; 13 533 HSP; 4414
BRZ; Supplementary Material, Table S2) participated in stage
2 and performed association analyses of 4373 variants that
were identified in stage 1 as either genome-wide significant
(P<5× 10-8) or suggestive (P<10-6). ASN participants include
both southAsian and east Asians. Stage 1 ASN includes 7873 East
Asians and 5566 South Asians, whereas stage 2 ASN includes
136961 East Asians and 12481 South Asians. All participating
studies are described in the Supplementary Material. Since
discoveries of BP loci to date were largely from EUR populations,
considerable effort wasmade for recruitingmost of the available
non-EUR cohorts into stage 1 (which limited the availability
of non-EUR cohorts in stage 2). Each study obtained informed
consent from participants and approval from the appropriate
institutional review boards.
Phenotypes and lifestyle variables
Resting SBP and DBP were measured using standard clinical
procedures that produce comparable measurements (specific
methods per studywere describedmore in SupplementaryMate-
rial). Even with some difference in measurement across studies,
the measures were standardized, through previous main effect
BP GWAS studies, as much as possible for BP. For individuals on
any anti-hypertensive (BP lowering) medications, 15 mmHg and
10 mmHg were added to their SBP and DBP values, respectively
(1). PP was computed as SBP minus DBP (PP=SBP—DBP), and
MAP was computed as the sum of DBP and one-third of PP
(MAP=DBP+PP/3). To reduce the influence of possible outliers,
each BP value was winsorized at six standard deviations (SD)
away from the mean (i.e. values greater than six SD away from
the mean were set at six SD).
Obtained through interview-based or self-reported ques-
tionnaire, varying levels of smoking information were available
across studies, some with a simple binary variable and others
with repeated data. We considered two of the most widely
available smoking variables: ‘current smoking’ status (CurSmk)
and ‘ever smoking’ status (EverSmk) (Table 1). Current smoking
status was defined as 1 if the individual smoked regularly in past
year (and as 0 for non-current smokers, which includes both
never and former smokers). Ever smoking status was defined
as 1 if the individual smoked at least 100 cigarettes during
his/her lifetime (and as 0 for the never smokers). Smoking
status was assessed at the time of the BP measurements.
Covariates include age, sex, field center (formulti-center studies)
and principal components (PCs) (to account for population
stratification and admixture). No additional covariates were
included. Individuals with missing data for BP, the smoking
variable or any covariates were excluded from analysis. Study-
specific summary statistics on phenotypes are presented in
Supplementary Materials, Tables S3 and S4.
Genotype data
Genotyping was obtained using Illumina (San Diego, CA, USA) or
Affymetrix (Santa Clara, CA, USA) genotyping arrays. Each study
performed genotype imputation at SNPs, short insertions and
deletions (indels), and larger deletions that were not genotyped
directly but are available from the 1000 Genomes Project (92).
For imputation, most studies used the 1000 Genomes Project
Phase I Integrated Release Version 3 Haplotypes (2010–11 data
freeze, 2012-03-14 haplotypes), which contain haplotypes of
1092 individuals of all ancestry backgrounds. Study-specific
information on genotyping and imputation is presented in
Supplementary Materials,Tables S5 and S6.
Cohort-specific analysis
We identified loci through the two DF test that jointly test the
genetic main effect and the gene–smoking interaction jointly.
This approach has previously enabled identification of new loci
associated with insulin resistance, including how the effect of
variants differs with levels of BMI (11). The method is described
in detail for single studies in Kraft et al. (93) and for implemen-
tation in meta-analyses in Manning et al. (24).
Participating studies performed association analyses sep-
arately within each ancestry for MAP and PP incorporating
CurSmk and EverSmk. All studies performed regression analysis
using a model with both genetic main and G×E interaction
effects (93): E
[
Y
]
= β0 + βESmk + βGG + βGESmk ∗ G + βCC.
Y is the medication-adjusted BP value, Smk is the smok-
ing variable (with 0/1 coding for the absence/presence of the
smoking exposure), G is the dosage of the imputed genetic
variant coded additively (from 0 to 2) and C is the vector of all
other covariates, which include age, sex, field center (for multi-
center studies) and PCs (to account for population stratification
and admixture). No additional cohort-specific covariates were
included. From this model, the studies provided the estimated
genetic main and interaction effects and a robust estimate of
the corresponding covariance matrix. In addition, studies in
stage 1 performed regression analyses with the genetic main-
effect model, in the exposed (Smk=1) and unexposed strata
(Smk=0) separately, and provided estimates of the stratum-
specific effects and robust estimates of their standard errors (SE).
Either sandwich (94) or ProbABEL (95) packages were used
to obtain robust estimates of covariance matrices and robust
SEs for samples of unrelated individuals. Family studies used
the generalized estimating equations approach, treating each
family as a cluster, or the linear mixed effect model approach
with a random polygenic component (for which the covariance
matrix depends on the kinship matrix). Robust estimates of
covariancematrices and SEswere used to safeguard againstmis-
specification of themeanmodel and violation of the assumption
of constant BP variance across smoking groups (heteroscedastic-
ity) (96,97).
Quality control
Each study performed standard genotype quality control (QC)
that includes excluding SNPs with call rate (<95% or higher) and
Hardy–Weinberg equilibrium P<10−6. In addition,we performed
extensive QC using the R package EasyQC (98) for all cohort-
specific results. For GWAS results in stage 1, each cohort applied
a preliminary filter on their imputed data excluding variants
with MAF<1%. Variants with imputation quality measure of
<0.5 were subsequently excluded. We performed the ‘study-
level’ QC, which included carefully checking the observed allele
frequencies against the corresponding ancestry-specific 1000
Genomes Project data and harmonizingmarker names to ensure
consistencies across cohorts. In addition, in stage 1, we com-
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pared results from the joint and stratified models, as explained
elsewhere (99).To identify cross-study issues,we thenperformed
the ‘meta-level’ QC by checking result files across all cohorts
for each analysis. This included visually comparing summary
statistics (mean, median, inter-quartile range, etc.) on all effect
estimates, SEs and P-values, and examining SE-N (i.e., inverse of
the median standard error versus the square root of the sample
size) plots andQQplots to reveal issueswith trait transformation
(98) or other analytical problems. EncounteredQCproblemswere
communicated and resolved with the individual cohorts. More
detailed information about QC is described elsewhere (13,16).
Meta-analyses
After selecting high-quality variants through extensive QC,
∼18.8 million SNPs and small indels variants were included in
the meta-analysis (the number of variants varied across the
ancestry groups). To combine cohort-specific results within
each ancestry, we first performed ancestry-specific meta-
analyses; the resultswere then combined throughmeta-analysis
to obtain evidence of ‘trans-ancestry’ association. Inverse-
variance-weighted meta-analysis with METAL (100) was used
for the one DF test of interaction effect (with H0: βGE = 0). For
two DF test of both SNP main and interaction effects (with H0:
βG =βGE = 0), the joint meta-analysis of Manning et al. (24) was
used. In the stratified model, we performed meta-analysis using
the approach of Randall et al. (101) for the one DF test and the
approach of Aschard et al. (102) for the two DF test using the
R package EasyStrata (103). Additional details about the meta-
analytic approach are described elsewhere (99).
In stage 1, genomic control correction (104) was applied twice,
first for cohort-specific GWAS results if their genomic control
lambda value was greater than 1 and again after the meta-
analysis.Variants that passedQCwere excluded if theywere rep-
resented in fewer than 5000 samples or fewer than three cohorts.
Variants that were genome-wide significant (P<5×10-8) or
suggestive (P<1× 10-6) in stage 1 were pursued in stage 2.
Heterogeneity P-values at the selected variants were >1×10-5,
indicating limited heterogeneity (data not shown). In stage 2,
genomic control correction was not applied to the replication
statistics as association analysis was performed only at select
variants. Meta-analysis combining results of stages 1 and 2 was
also performed. In addition, genome-wide significant variants
in stage 1 were tested for formal replication in stage 2 using
Bonferroni-corrected significance threshold.
Genome-wide significant variants
We considered a variant with P<5×10-8 (the standard threshold
in the field) to be genome-wide significant. We also identified
novel loci that pass a more stringent threshold (P<6.25×10−9,
P<5×10−8 adjusted for two smoking exposures, two tests and
two BP traits, where this correction is somewhat conservative
given dependence between the various test statistics). Loci that
pass the stricter P-value are indicated in main tables. FDR q-
values were computed using the R function p.adjust using the
step-up method by Benjamini and Hochberg (105). A new locus
was identified if it was 1 Mb away from any previously identified
BP locus.A new signal was identified if it is within 1Mb of known
BP loci but not in LD r2 <0.1 with the known BP loci. Since valid
methods do not exist for conditional analysis involving inter-
actions across multi-ancestry studies, we relied on a relatively
more stringent LD threshold (r2 <0.1) for identifying additional
signals. For LD reference, ancestry-specific 1000Genomes Project
data (106) were used for ancestry-specific results, and the entire
cosmopolitan data set was used for trans-ancestry results.
BP variance explained
We computed BP variance explained by genome-wide results,
based on stage 1 stratified results with current-smoking status
in European ancestry (25).Within each of the smoking strata, we
computed the variance of MAP and PP explained by subsets of
variants selected using 15 significance thresholds ranging from
1×10-8 to 0.1
Functional inferences
We conducted DEPICT analyses (107) based on genome-wide
significant (P<5× 10−8) variants from the combined analysis of
stages 1 and 2. DEPICT performs three consecutive analyses: i)
gene prioritization at the identified loci, ii) gene set enrichment
analyses and iii) tissue- and cell-type-specific expression analy-
ses. To obtain input for the analyses, DEPICT applied a combined
distance and LD-based threshold (500 kb flanking regions and LD
r2 >0.1) between the identified variants and the 1000 Genomes
reference data (106). A further clumping (LD r2 >0.5 between the
non-overlapping variants and known functional coding or cis-
acting regulatory variants) was used to obtain a list of genes
overlapping with the identified variants. The major histocom-
patibility complex region on chromosome 6 (25—35 Mb) was
removed for further analyses.
For gene prioritization, DEPICT compared functional simi-
larity of genes across identified loci using a gene score, which
was adjusted for confounders like gene length. To obtain FDR,
the scoring was repeated 50× based on 500 pre-compiled null
GWAS. For gene-set enrichment analyses, DEPICT used 14461
pre-compiled reconstituted gene sets; they include 737 Reac-
tome pathways, 2473 phenotypic gene sets (derived from the
Mouse Genetics Initiative), 184 Kyoto Encyclopedia of Genes
and Genomes pathways, 5083 Gene Ontology terms and 5984
proteinmolecular pathways (derived from protein–protein inter-
actions). For tissue- and cell-type enrichment analyses, DEPICT
used expression data from the 209 MeSH annotations for 37 427
microarrays of the Affymetrix U133 Plus 2.0 Array platform.
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We thank anonymous reviewers for critical reading and provid-
ing constructive and insightful comments, which substantially
improved the article. This project, like several other projects,was
carried out as part of the CHARGE Gene–Lifestyle Interactions
Working Group.
Conflict of Interest statement. The authors declare no competing
financial interests except for the following: B.M.P. serves on the
Data and SafetyMonitoring Board of a clinical trial funded by the
manufacturer (Zoll LifeCor) and on the Steering Committee of
the Yale Open Data Access Project funded by Johnson & Johnson;
O.H.F. received grants from Metagenics (on women’s health and
epigenetics) and fromNestle (on child health); L.J.B. is listed as an
inventor on Issued U.S. Patent 8,080,371,‘Markers for Addiction’
covering the use of certain SNPs in determining the diagnosis,
prognosis and treatment of addiction; P.S. has received research
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/15/2615/5439584 by H
ulib user on 15 N
ovem
ber 2019
2630 Human Molecular Genetics, 2019, Vol. 28, No. 15
awards from Pfizer Inc; J.B.J. is a consultant for Mundipharma
Co. (Cambridge, UK), Patent holder with Biocompatibles UK Ltd
(Franham, Surrey, UK) (title: treatment of eye diseases using
encapsulated cells encoding and secreting neuroprotective fac-
tor and/or anti-angiogenic factor; Patent number: 20120263794)
and Patent applicationwithUniversity of Heidelberg (Heidelberg,
Germany) (title: agents for use in the therapeutic or prophylactic
treatment of myopia or hyperopia; Europäische Patentanmel-
dung 15000771.4); P.W.F. has been a paid consultant for Eli Lilly
and Sanofi Aventis and has received research support from
several pharmaceutical companies as part of a European Union
Innovative Medicines Initiative project; M.A.N.’s participation
is supported by a consulting contract between Data Tecnica
International and the National Institute on Aging,National Insti-
tutes of Health, Bethesda, MD, USA; M.A.N. also consults for
Illumina Inc, the Michael J. Fox Foundation and University of
California Healthcare among others; and M.J. C. is chief scientist
for Genomics England, a UK government company.
Funding
U.S. National Heart, Lung, and Blood Institute (NHLBI) (K25HL1
21091 to Y.J.S.); National Institutes of Health (R01HL118305).
References
1. Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M.D.,
Bochud, M., Coin, L., Najjar, S.S., Zhao, J.H., Heath, S.C.,
Eyheramendy, S. et al. (2009) Genome-wide association
study identifies eight loci associated with blood pressure.
Nat. Genet., 41, 666–676.
2. Levy, D., Ehret, G.B., Rice, K., Verwoert, G.C., Launer, L.J.,
Dehghan, A., Glazer, N.L., Morrison, A.C., Johnson, A.D.,
Aspelund, T. et al. (2009) Genome-wide association study of
blood pressure and hypertension. Nat. Genet., 41, 677–687.
3. Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson,
A.D., Chasman, D.I., Smith, A.V., Tobin, M.D., Verwoert, G.C.,
Hwang, S.J. et al. (2011) Genetic variants in novel pathways
influence blood pressure and cardiovascular disease risk.
Nature, 478, 103–109.
4. Ehret, G.B., Ferreira, T., Chasman, D.I., Jackson, A.U.,
Schmidt, E.M., Johnson, T., Thorleifsson, G., Luan, J.,
Donnelly, L.A., Kanoni, S. et al. (2016) The genetics of blood
pressure regulation and its target organs from association
studies in 342415 individuals. Nat. Genet., 48, 1171–1184.
5. Liu, C., Kraja, A.T., Smith, J.A., Brody, J.A., Franceschini,
N., Bis, J.C., Rice, K., Morrison, A.C., Lu, Y., Weiss, S. et al.
(2016) Meta-analysis identifies common and rare variants
influencing blood pressure and overlappingwithmetabolic
trait loci. Nat. Genet., 48, 1162–1170.
6. Surendran, P., Drenos, F., Young, R., Warren, H., Cook, J.P.,
Manning, A.K., Grarup, N., Sim, X., Barnes, D.R., Witkowska,
K. et al. (2016) Trans-ancestry meta-analyses identify rare
and common variants associated with blood pressure and
hypertension. Nat. Genet., 48, 1151–1161.
7. Hoffmann, T.J., Ehret, G.B., Nandakumar, P., Ranatunga, D.,
Schaefer, C., Kwok, P.Y., Iribarren, C., Chakravarti, A. and
Risch, N. (2016) Genome-wide association analyses using
electronic health records identify new loci influencing
blood pressure variation. Nat. Genet., 49, 54–64.
8. Warren, H.R., Evangelou, E., Cabrera, C.P., Gao, H., Ren, M.,
Mifsud, B., Ntalla, I., Surendran, P., Liu, C., Cook, J.P. et al.
(2017) Genome-wide association analysis identifies novel
blood pressure loci and offers biological insights into car-
diovascular risk. Nat. Genet., 49, 403–415.
9. Evangelou, E., Warren, H.R., Mosen-Ansorena, D., Mifsud,
B., Pazoki, R., Gao, H., Ntritsos, G., Dimou, N., Cabrera, C.P.,
Karaman, I. et al. (2018) Genetic analysis of over 1 million
people identifies 535 new loci associated with blood pres-
sure traits. Nat. Genet., 50, 1412–1425.
10. Giri, A., Hellwege, J.N., Keaton, J.M., Park, J., Qiu, C., Warren,
H.R., Torstenson, E.S., Kovesdy, C.P., Sun, Y.V., Wilson, O.D.
et al. (2019) Trans-ethnic association study of blood pres-
sure determinants in over 750000 individuals. Nat. Genet.,
51, 51–62.
11. Manning, A.K., Hivert, M.F., Scott, R.A., Grimsby, J.L.,
Bouatia-Naji, N., Chen, H., Rybin, D., Liu, C.T., Bielak,
L.F., Prokopenko, I. et al. (2012) A genome-wide approach
accounting for body mass index identifies genetic variants
influencing fasting glycemic traits and insulin resistance.
Nat. Genet., 44, 659–669.
12. Kirk, E.P. (2017) Genes, environment, and the heart: putting
the pieces together. Circ. Cardiovasc. Genet., 10, 1–2.
13. Rao, D.C., Sung, Y.J., Winkler, T.W., Schwander, K., Borecki,
I., Cupples, L.A., Gauderman, W.J., Rice, K., Munroe, P.B. and
Psaty, B. (2017) A multi-ancestry study of gene–lifestyle
interactions for cardiovascular traits in 610475 individuals
from 124 cohorts: design and rationale. Circ. Cardiovasc.
Genet., 10, e001649.
14. Mann, S.J., James, G.D., Wang, R.S. and Pickering, T.G.
(1991) Elevation of ambulatory systolic blood pressure in
hypertensive smokers. A case–control study. JAMA, 265,
2226–2228.
15. Primatesta, P., Falaschetti, E., Gupta, S., Marmot, M.G. and
Poulter,N.R. (2001) Association between smoking and blood
pressure: evidence from the health survey for England.
Hypertension, 37, 187–193.
16. Sung, Y.J., Winkler, T.W., de Las Fuentes, L., Bentley, A.R.,
Brown, M.R., Kraja, A.T., Schwander, K., Ntalla, I., Guo, X.,
Franceschini, N. et al. (2018) A large-scale multi-ancestry
genome-wide study accounting for smoking behavior iden-
tifies multiple significant loci for blood pressure. Am. J.
Hum. Genet., 102, 375–400.
17. Franklin, S.S., Gustin,W.t., Wong, N.D., Larson, M.G.,Weber,
M.A., Kannel, W.B. and Levy, D. (1997) Hemodynamic pat-
terns of age-related changes in blood pressure. The Fram-
ingham heart study. Circulation, 96, 308–315.
18. Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R.
and Prospective Studies Collaboration (2002) Age-specific
relevance of usual blood pressure to vascular mortality: a
meta-analysis of individual data for one million adults in
61 prospective studies. Lancet, 360, 1903–1913.
19. Sesso, H.D., Stampfer, M.J., Rosner, B., Hennekens, C.H.,
Gaziano, J.M.,Manson, J.E. and Glynn, R.J. (2000) Systolic and
diastolic blood pressure, pulse pressure, and mean arterial
pressure as predictors of cardiovascular disease risk in
men. Hypertension, 36, 801–807.
20. Dart, A.M. and Kingwell, B.A. (2001) Pulse pressure—a
review of mechanisms and clinical relevance. J. Am. Coll.
Cardiol., 37, 975–984.
21. Franklin, S.S., Khan, S.A., Wong, N.D., Larson, M.G. and
Levy, D. (1999) Is pulse pressure useful in predicting risk
for coronary heart disease? The Framingham heart study.
Circulation, 100, 354–360.
22. Millar, J.A., Lever, A.F. and Burke, V. (1999) Pulse pressure
as a risk factor for cardiovascular events in the MRC mild
hypertension trial. J. Hypertens., 17, 1065–1072.
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/15/2615/5439584 by H
ulib user on 15 N
ovem
ber 2019
Human Molecular Genetics, 2019, Vol. 28, No. 15 2631
23. Whelton, P.K., Carey, R.M., Aronow, W.S., Casey, D.E.,.J.,
Collins, K.J., Dennison Himmelfarb, C., DePalma, S.M.,
Gidding, S., Jamerson, K.A., Jones, D.W. et al. (2018)
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/
NMA/PCNA guideline for the prevention, detection,
evaluation, and management of high blood pressure in
adults: a report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice
Guidelines. J. Am. Coll. Cardiol., 71, e127–e248.
24. Manning, A.K., LaValley, M., Liu, C.T., Rice, K., An, P., Liu,
Y., Miljkovic, I., Rasmussen-Torvik, L., Harris, T.B., Province,
M.A. et al. (2011) Meta-analysis of gene–environment inter-
action: joint estimation of SNP and SNP × environment
regression coefficients. Genet. Epidemiol., 35, 11–18.
25. Kutalik, Z., Whittaker, J., Waterworth, D., Consortium, G.,
Beckmann, J.S. and Bergmann, S. (2011) Novel method to
estimate the phenotypic variation explained by genome-
wide association studies reveals large fraction of the miss-
ing heritability. Genet. Epidemiol., 35, 341–349.
26. Ward, L.D. and Kellis, M. (2012) HaploReg: a resource for
exploring chromatin states, conservation, and regulatory
motif alterations within sets of genetically linked variants.
Nucleic Acids Res., 40, D930–D934.
27. Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow,
A. and Batzoglou, S. (2010) Identifying a high fraction of
the human genome to be under selective constraint using
GERP++. PLoS Comput. Biol., 6, e1001025.
28. Garber,M.,Guttman,M.,Clamp,M., Zody,M.C., Friedman,N.
andXie,X. (2009) Identifying novel constrained elements by
exploiting biased substitution patterns. Bioinformatics, 25,
i54–i62.
29. Consortium, G.T. (2015) Human genomics. The genotype-
tissue expression (GTEx) pilot analysis: multitissue gene
regulation in humans. Science, 348, 648–660.
30. Joehanes, R., Zhang, X., Huan, T., Yao, C., Ying, S.X., Nguyen,
Q.T., Demirkale, C.Y., Feolo, M.L., Sharopova, N.R., Sturcke,
A. et al. (2017) Integrated genome-wide analysis of expres-
sion quantitative trait loci aids interpretation of genomic
association studies. Genome Biol., 18, 16.
31. di Salvo, T.G., Yang, K.C., Brittain, E., Absi, T., Maltais, S. and
Hemnes, A. (2015) Right ventricular myocardial biomarkers
in human heart failure. J. Card. Fail., 21, 398–411.
32. Cingolani, O.H., Kirk, J.A., Seo, K., Koitabashi, N., Lee, D.I.,
Ramirez-Correa, G., Bedja, D., Barth, A.S., Moens, A.L. and
Kass, D.A. (2011) Thrombospondin-4 is required for stretch-
mediated contractility augmentation in cardiac muscle.
Circ. Res., 109, 1410–1414.
33. Han, Y., Chen, Y.S., Liu, Z., Bodyak, N., Rigor, D., Bisping, E.,
Pu,W.T. and Kang, P.M. (2006) Overexpression of HAX-1 pro-
tects cardiac myocytes from apoptosis through caspase-9
inhibition. Circ. Res., 99, 415–423.
34. Lee, B.Y., Chon, J., Kim, H.S., Lee, J.H., Yun, D.H., Yoo, S.D.,
Kim, D.H., Lee, S.A., Han, Y.J., Lee, H. et al. (2017) Association
between a polymorphism in CASP3 and CASP9 genes and
ischemic stroke. Ann. Rehabil. Med., 41, 197–203.
35. Elliott, H.R., Tillin, T., McArdle, W.L., Ho, K., Duggirala, A.,
Frayling, T.M., Davey Smith, G., Hughes, A.D., Chaturvedi, N.
and Relton, C.L. (2014) Differences in smoking associated
DNAmethylation patterns in South Asians and Europeans.
Clin. Epigenetics, 6, 4.
36. Markunas, C.A., Xu, Z., Harlid, S.,Wade, P.A., Lie, R.T., Taylor,
J.A. and Wilcox, A.J. (2014) Identification of DNA methy-
lation changes in newborns related to maternal smoking
during pregnancy. Environ. Health Perspect., 122, 1147–1153.
37. Begum, N., Hockman, S. and Manganiello, V.C. (2011) Phos-
phodiesterase 3A (PDE3A) deletion suppresses proliferation
of cultured murine vascular smooth muscle cells (VSMCs)
via inhibition of mitogen-activated protein kinase (MAPK)
signaling and alterations in critical cell cycle regulatory
proteins. J. Biol. Chem., 286, 26238–26249.
38. Maass, P.G., Aydin, A., Luft, F.C., Schachterle, C., Weise,
A., Stricker, S., Lindschau, C., Vaegler, M., Qadri, F., Toka,
H.R. et al. (2015) PDE3A mutations cause autosomal dom-
inant hypertension with brachydactyly. Nat. Genet., 47,
647–653.
39. Toka, O., Tank, J., Schachterle, C., Aydin, A., Maass, P.G.,
Elitok, S., Bartels-Klein, E., Hollfinger, I., Lindschau, C., Mai,
K. et al. (2015) Clinical effects of phosphodiesterase 3A
mutations in inherited hypertension with brachydactyly.
Hypertension, 66, 800–808.
40. Vasan, R.S., Glazer, N.L., Felix, J.F., Lieb, W., Wild, P.S., Felix,
S.B., Watzinger, N., Larson, M.G., Smith, N.L., Dehghan, A.
et al. (2009) Genetic variants associated with cardiac struc-
ture and function: a meta-analysis and replication of
genome-wide association data. JAMA, 302, 168–178.
41. Fontana, V., McDonough, C.W., Gong, Y., El Rouby, N.M., Sa,
A.C., Taylor, K.D., Chen, Y.D., Gums, J.G., Chapman, A.B.,
Turner, S.T. et al. (2014) Large-scale gene-centric analysis
identifies polymorphisms for resistant hypertension. J. Am.
Heart Assoc., 3, e001398.
42. Simino, J., Sung, Y.J., Kume, R., Schwander, K. and Rao,
D.C. (2013) Gene–alcohol interactions identify several novel
blood pressure loci including a promising locus near
SLC16A9. Front. Genet., 4, 277.
43. Coan, P.M., Hummel, O., Garcia Diaz, A., Barrier, M.,
Alfazema, N., Norsworthy, P.J., Pravenec, M., Petretto, E.,
Hubner, N. and Aitman, T.J. (2017) Genetic, physiological
and comparative genomic studies of hypertension and
insulin resistance in the spontaneously hypertensive rat.
Dis. Model. Mech., 10, 297–306.
44. Hong, K.W., Go, M.J., Jin, H.S., Lim, J.E., Lee, J.Y., Han, B.G.,
Hwang, S.Y., Lee, S.H., Park, H.K., Cho, Y.S. et al. (2010)
Genetic variations in ATP2B1, CSK, ARSG and CSMD1 loci
are related to blood pressure and/or hypertension in two
Korean cohorts. J. Hum. Hypertens., 24, 367–372.
45. Koriyama, H., Nakagami, H., Katsuya, T., Sugimoto, K.,
Yamashita, H., Takami, Y., Maeda, S., Kubo, M., Takahashi,
A., Nakamura, Y. et al. (2010) Identification of evidence sug-
gestive of an association with peripheral arterial disease
at the OSBPL10 locus by genome-wide investigation in the
Japanese population. J. Atheroscler. Thromb., 17, 1054–1062.
46. Liu, C.T., Monda, K.L., Taylor, K.C., Lange, L., Demerath,
E.W., Palmas, W., Wojczynski, M.K., Ellis, J.C., Vitolins, M.Z.,
Liu, S. et al. (2013) Genome-wide association of body fat
distribution in African ancestry populations suggests new
loci. PLoS Genet., 9, e1003681.
47. Irvin, M.R., Wineinger, N.E., Rice, T.K., Pajewski, N.M.,
Kabagambe, E.K., Gu, C.C., Pankow, J., North, K.E., Wilk, J.B.,
Freedman, B.I. et al. (2011) Genome-wide detection of allele
specific copy number variation associated with insulin
resistance in African Americans from the HyperGEN study.
PLoS One, 6, e24052.
48. Uhl, G.R., Drgon, T., Johnson, C., Li, C.Y., Contoreggi, C.,
Hess, J., Naiman, D. and Liu, Q.R. (2008) Molecular genetics
of addiction and related heritable phenotypes: genome-
wide association approaches identify ‘connectivity con-
stellation’ and drug target genes with pleiotropic effects.
Ann. N. Y. Acad. Sci., 1141, 318–381.
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/15/2615/5439584 by H
ulib user on 15 N
ovem
ber 2019
2632 Human Molecular Genetics, 2019, Vol. 28, No. 15
49. Moon, S.H., Kim, Y.J., Kim, Y.K., Kim, D.J., Lee, J.Y., Go, M.J.,
Shin, Y.A., Hong, C.B. and Kim, B.J. (2011) Genome-wide
survey of copy number variants associatedwith blood pres-
sure and bodymass index in a Korean population.Genomics
Informatics 9, 152–160.
50. Petrovic, S., Barone, S., Xu, J., Conforti, L., Ma, L., Kujala,
M., Kere, J. and Soleimani, M. (2004) SLC26A7: a basolateral
cl-/HCO3- exchanger specific to intercalated cells of the
outer medullary collecting duct.Am. J. Physiol. Renal Physiol.,
286, F161–F169.
51. Henke, N., Schmidt-Ullrich, R., Dechend, R., Park, J.K., Qadri,
F., Wellner, M., Obst, M., Gross, V., Dietz, R., Luft, F.C. et al.
(2007) Vascular endothelial cell-specific NF-kappaB sup-
pression attenuates hypertension-induced renal damage.
Circ. Res., 101, 268–276.
52. Pierce, G.L., Lesniewski, L.A., Lawson, B.R., Beske, S.D. and
Seals, D.R. (2009) Nuclear factor-{kappa}B activation con-
tributes to vascular endothelial dysfunction via oxidative
stress in overweight/obesemiddle-aged and older humans.
Circulation, 119, 1284–1292.
53. Duan, P., Wang, Z.M., Liu, J., Wang, L.N., Yang, Z. and Tu,
P. (2015) Association of gene polymorphisms in RANKL/
RANK/OPG system with hypertension and blood pressure
in Chinese women. J. Hum. Hypertens., 29, 749–753.
54. Woods, R.L. and Johnston, C.I. (1983) Contribution of vaso-
pressin to the maintenance of blood pressure during dehy-
dration. Am. J. Physiol., 245, F615–F621.
55. Aoyagi, T., Izumi, Y., Hiroyama, M., Matsuzaki, T., Yasuoka,
Y., Sanbe,A.,Miyazaki,H., Fujiwara,Y.,Nakayama,Y.,Kohda,
Y. et al. (2008) Vasopressin regulates the renin-angiotensin-
aldosterone system via V1a receptors in macula densa
cells. Am. J. Physiol. Renal Physiol., 295, F100–F107.
56. Koshimizu, T.A., Nasa, Y., Tanoue, A., Oikawa, R., Kawahara,
Y., Kiyono, Y., Adachi, T., Tanaka, T., Kuwaki, T., Mori, T.
et al. (2006) V1a vasopressin receptors maintain normal
blood pressure by regulating circulating blood volume and
baroreflex sensitivity. Proc. Natl. Acad. Sci. U. S. A., 103,
7807–7812.
57. Burrell, L.M., Phillips, P.A., Risvanis, J., Aldred,K.L., Hutchins,
A.M. and Johnston, C.I. (1995) Attenuation of genetic hyper-
tension after short-term vasopressin V1A receptor antago-
nism. Hypertension, 26, 828–834.
58. Ronzaud, C., Loffing-Cueni, D., Hausel, P., Debonneville,
A., Malsure, S.R., Fowler-Jaeger, N., Boase, N.A., Perrier, R.,
Maillard, M., Yang, B. et al. (2013) Renal tubular NEDD4-
2 deficiency causes NCC-mediated salt-dependent hyper-
tension. J. Clin. Invest., 123, 657–665.
59. Debonneville, C., Flores, S.Y., Kamynina, E., Plant, P.J.,
Tauxe, C., Thomas, M.A., Munster, C., Chraibi, A., Pratt, J.H.,
Horisberger, J.D. et al. (2001) Phosphorylation of Nedd4-
2 by Sgk1 regulates epithelial Na(+) channel cell surface
expression. EMBO J., 20, 7052–7059.
60. Zheng, X., Morrison, A.C., Feingold, E., Turner, S.T. and
Ferrell, R.E. (2011) Association between NEDD4L gene and
sodium lithium countertransport. Am. J. Hypertens., 24,
145–148.
61. Luo, F., Wang, Y., Wang, X., Sun, K., Zhou, X. and Hui, R.
(2009) A functional variant of NEDD4L is associated with
hypertension, antihypertensive response, and orthostatic
hypotension. Hypertension, 54, 796–801.
62. Svensson-Farbom, P., Wahlstrand, B., Almgren, P., Dahlberg,
J., Fava, C., Kjeldsen, S., Hedner, T. and Melander, O. (2011)
A functional variant of the NEDD4L gene is associated
with beneficial treatment response with beta-blockers
and diuretics in hypertensive patients. J. Hypertens., 29,
388–395.
63. McDonough, C.W., Burbage, S.E., Duarte, J.D., Gong, Y.,
Langaee, T.Y., Turner, S.T., Gums, J.G., Chapman, A.B., Bailey,
K.R., Beitelshees, A.L. et al. (2013) Association of variants in
NEDD4L with blood pressure response and adverse cardio-
vascular outcomes in hypertensive patients treated with
thiazide diuretics. J. Hypertens., 31, 698–704.
64. Goldberg, L.I. (1972) Cardiovascular and renal actions of
dopamine: potential clinical applications. Pharmacol. Rev.,
24, 1–29.
65. Li, X.X., Bek,M., Asico, L.D., Yang, Z., Grandy, D.K., Goldstein,
D.S., Rubinstein, M., Eisner, G.M. and Jose, P.A. (2001) Adren-
ergic and endothelin B receptor-dependent hypertension in
dopamine receptor type-2 knockout mice. Hypertension, 38,
303–308.
66. Armando, I., Wang, X., Villar, V.A., Jones, J.E., Asico,
L.D., Escano, C. and Jose, P.A. (2007) Reactive oxygen
species-dependent hypertension in dopamine D2 receptor-
deficient mice. Hypertension, 49, 672–678.
67. Zhang, Y., Jiang, X., Qin, C., Cuevas, S., Jose, P.A. and
Armando, I. (2016) Dopamine D2 receptors’ effects on renal
inflammation aremediated by regulation of PP2A function.
Am. J. Physiol. Renal Physiol., 310, F128–F134.
68. Yang, Y., Cuevas, S., Yang, S., Villar, V.A., Escano, C., Asico,
L., Yu, P., Jiang, X., Weinman, E.J., Armando, I. et al. (2014)
Sestrin2 decreases renal oxidative stress, lowers blood
pressure, and mediates dopamine D2 receptor-induced
inhibition of reactive oxygen species production. Hyperten-
sion, 64, 825–832.
69. Yi, L., Li, F., Yong,Y., Jianting,D., Liting, Z., Xuansheng,H., Fei,
L. and Jiewen, L. (2014) Upregulation of sestrin-2 expression
protects against endothelial toxicity of angiotensin II. Cell
Biol. Toxicol., 30, 147–156.
70. Paisan-Ruiz, C., Guevara, R., Federoff, M., Hanagasi, H., Sina,
F., Elahi, E., Schneider, S.A., Schwingenschuh, P., Bajaj, N.,
Emre,M. et al. (2010) Early-onset L-dopa-responsive parkin-
sonism with pyramidal signs due to ATP13A2, PLA2G6,
FBXO7 and spatacsinmutations.Mov.Disord.,25, 1791–1800.
71. Ouimet, C.C., Hemmings, H.C., Jr. and Greengard, P. (1989)
ARPP-21, a cyclic AMP-regulated phosphoprotein enriched
in dopamine-innervated brain regions. II. Immunocyto-
chemical localization in rat brain. J. Neurosci., 9, 865–875.
72. Pierce, R.C. and Kumaresan, V. (2006) The mesolimbic
dopamine system: the final common pathway for the rein-
forcing effect of drugs of abuse? Neurosci. Biobehav. Rev., 30,
215–238.
73. King,K.S. and Pacak,K. (2014) Familial pheochromocytomas
and paragangliomas.Mol. Cell. Endocrinol., 386, 92–100.
74. Hes, F.J., Weiss, M.M., Woortman, S.A., de Miranda, N.F., van
Bunderen, P.A., Bonsing, B.A., Stokkel, M.P., Morreau, H.,
Romijn, J.A., Jansen, J.C. et al. (2010) Low penetrance of a
SDHBmutation in a largeDutch paraganglioma family.BMC
Med. Genet., 11, 92.
75. Parmar, P.G., Taal, H.R., Timpson, N.J., Thiering, E.,
Lehtimaki, T., Marinelli, M., Lind, P.A., Howe, L.D.,
Verwoert, G., Aalto, V. et al. (2016) International genome-
wide association study consortium identifies novel
loci associated with blood pressure in children and
adolescents. Circ. Cardiovasc. Genet., 9, 266–278.
76. Luecke, S., Backlund, M., Jux, B., Esser, C., Krutmann, J. and
Rannug, A. (2010) The aryl hydrocarbon receptor (AHR),
a novel regulator of human melanogenesis. Pigment Cell
Melanoma Res., 23, 828–833.
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/15/2615/5439584 by H
ulib user on 15 N
ovem
ber 2019
Human Molecular Genetics, 2019, Vol. 28, No. 15 2633
77. Wang, L., Chu, A., Buring, J.E., Ridker, P.M., Chasman, D.I.
and Sesso, H.D. (2014) Common genetic variations in the
vitamin D pathway in relation to blood pressure. Am. J.
Hypertens., 27, 1387–1395.
78. Blacher, J., Staessen, J.A., Girerd, X., Gasowski, J., Thijs, L.,
Liu, L., Wang, J.G., Fagard, R.H. and Safar, M.E. (2000) Pulse
pressure not mean pressure determines cardiovascular
risk in older hypertensive patients. Arch. Intern. Med., 160,
1085–1089.
79. Gasowski, J., Fagard, R.H., Staessen, J.A., Grodzicki, T.,
Pocock, S., Boutitie, F., Gueyffier, F., Boissel, J.P. and Collab-
orators, I.P. (2002) Pulsatile blood pressure component as
predictor of mortality in hypertension: a meta-analysis of
clinical trial control groups. J. Hypertens., 20, 145–151.
80. Gambier, N., Marteau, J.B., Batt, A.M., Marie, B., Thompson,
A., Siest, G., Foernzler, D. and Visvikis-Siest, S. (2006) Inter-
action between CYP1A1 T3801C and AHR G1661A polymor-
phisms according to smoking status on blood pressure in
the Stanislas cohort. J. Hypertens., 24, 2199–2205.
81. Lund, A.K., Goens, M.B., Nunez, B.A. andWalker, M.K. (2006)
Characterizing the role of endothelin-1 in the progression
of cardiac hypertrophy in aryl hydrocarbon receptor (AhR)
null mice. Toxicol. Appl. Pharmacol., 212, 127–135.
82. Niermann, T., Schmutz, S., Erne, P. and Resink, T. (2003) Aryl
hydrocarbon receptor ligands repress T-cadherin expres-
sion in vascular smooth muscle cells. Biochem. Biophys. Res.
Commun., 300, 943–949.
83. Kuzmenko, Y.S., Kern, F., Bochkov, V.N., Tkachuk, V.A.
and Resink, T.J. (1998) Density- and proliferation status-
dependent expression of T-cadherin, a novel lipoprotein-
binding glycoprotein: a function in negative regulation of
smooth muscle cell growth? FEBS Lett., 434, 183–187.
84. Org, E., Eyheramendy, S., Juhanson, P., Gieger, C., Lichtner,
P., Klopp, N., Veldre, G., Doring, A., Viigimaa, M., Sober, S.
et al. (2009) Genome-wide scan identifies CDH13 as a novel
susceptibility locus contributing to blood pressure determi-
nation in two European populations. Hum. Mol. Genet., 18,
2288–2296.
85. Nguyen, L.P. and Bradfield, C.A. (2008) The search for
endogenous activators of the aryl hydrocarbon receptor.
Chem. Res. Toxicol., 21, 102–116.
86. Martey, C.A., Baglole, C.J., Gasiewicz, T.A., Sime, P.J. and
Phipps, R.P. (2005) The aryl hydrocarbon receptor is a reg-
ulator of cigarette smoke induction of the cyclooxygenase
and prostaglandin pathways in human lung fibroblasts.
Am. J. Physiol. Lung Cell. Mol. Physiol., 289, L391–L399.
87. Blacher, J. and Safar, M.E. (2005) Large-artery stiffness,
hypertension and cardiovascular risk in older patients.Nat.
Clin. Pract. Cardiovasc. Med., 2, 450–455.
88. Zollner, S. and Pritchard, J.K. (2007) Overcoming the win-
ner’s curse: estimating penetrance parameters from case-
control data. Am. J. Hum. Genet., 80, 605–615.
89. Bentley, A.R., Sung, Y.J., Brown, M.R., Winkler, T.W., Kraja,
A.T., Ntalla, I., Schwander, K., Chasman, D.I., Lim, E., Deng,
E. et al. (2019) Multi-ancestry genome-wide gene-smoking
interaction study of 387,272 individuals identifies new loci
associated with serum lipids.. Nature genetics, 51, 636–648.
90. Keller, M.C. (2014) Gene × environment interaction studies
have not properly controlled for potential confounders:
the problem and the (simple) solution. Biol. Psychiatry, 75,
18–24.
91. Tyrrell, J., Wood, A.R., Ames, R.M., Yaghootkar, H.,
Beaumont, R.N., Jones, S.E., Tuke, M.A., Ruth, K.S.,
Freathy, R.M., Davey Smith, G. et al. (2017) Gene-obesogenic
environment interactions in the UK biobank study. Int. J.
Epidemiol., 46, 559–575.
92. 1000 Genomes Project Consortium, Abecasis, G.R., Auton,
A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker,
R.E., Kang, H.M., Marth, G.T. and McVean, G.A. (2012) An
integrated map of genetic variation from 1092 human
genomes. Nature, 491, 56–65.
93. Kraft, P., Yen, Y.C., Stram, D.O., Morrison, J. and Gauder-
man, W.J. (2007) Exploiting gene–environment interaction
to detect genetic associations. Hum. Hered., 63, 111–119.
94. Zeileis, A. (2006) Object-oriented computation of sandwich
estimators. J. Stat. Softw., 16, 1–16.
95. Aulchenko, Y.S., Struchalin, M.V. and van Duijn, C.M. (2010)
ProbABEL package for genome-wide association analysis of
imputed data. BMC Bioinformatics, 11, 134.
96. Tchetgen Tchetgen, E.J. and Kraft, P. (2011) On the robust-
ness of tests of genetic associations incorporating gene–
environment interaction when the environmental expo-
sure is misspecified. Epidemiology, 22, 257–261.
97. Voorman, A., Lumley, T., McKnight, B. and Rice, K. (2011)
Behavior of QQ-plots and genomic control in studies of
gene–environment interaction. PLoS One, 6, e19416.
98. Winkler, T.W., Day, F.R., Croteau-Chonka, D.C., Wood, A.R.,
Locke,A.E.,Magi, R., Ferreira, T., Fall, T., Graff,M., Justice,A.E.
et al. (2014) Quality control and conduct of genome-wide
association meta-analyses. Nat. Protoc., 9, 1192–1212.
99. Sung, Y.J., Winkler, T.W., Manning, A.K., Aschard, H.,
Gudnason,V.,Harris, T.B., Smith,A.V., Boerwinkle, E., Brown,
M.R.,Morrison, A.C. et al. (2016) An empirical comparison of
joint and stratified frameworks for studying G × E interac-
tions: systolic blood pressure and smoking in the CHARGE
gene–lifestyle interactions working group.Genet. Epidemiol.,
40, 404–415.
100. Willer, C.J., Li, Y. and Abecasis, G.R. (2010) METAL: fast and
efficient meta-analysis of genomewide association scans.
Bioinformatics, 26, 2190–2191.
101. Randall, J.C., Winkler, T.W., Kutalik, Z., Berndt, S.I., Jackson,
A.U., Monda, K.L., Kilpelainen, T.O., Esko, T., Magi, R., Li, S.
et al. (2013) Sex-stratified genome-wide association stud-
ies including 270000 individuals show sexual dimorphism
in genetic loci for anthropometric traits. PLoS Genet., 9,
e1003500.
102. Aschard, H., Hancock, D.B., London, S.J. and Kraft, P. (2010)
Genome-wide meta-analysis of joint tests for genetic and
gene–environment interaction effects. Hum. Hered., 70,
292–300.
103. Winkler, T.W., Kutalik, Z., Gorski, M., Lottaz, C., Kronenberg,
F. and Heid, I.M. (2015) EasyStrata: evaluation and visualiza-
tion of stratified genome-wide association meta-analysis
data. Bioinformatics, 31, 259–261.
104. Devlin, B. and Roeder, K. (1999) Genomic control for associ-
ation studies. Biometrics, 55, 997–1004.
105. Benjamini, Y. and Hochberg, Y. (1995) Controlling the false
discovery rate—a practical and powerful approach to mul-
tiple testing. J. R. Stat. Soc. Series B Stat.Methodol.,57, 289–300.
106. Genomes Project, C., Abecasis, G.R., Altshuler, D., Auton,
A., Brooks, L.D., Durbin, R.M., Gibbs, R.A., Hurles, M.E. and
McVean, G.A. (2010) A map of human genome variation
from population-scale sequencing. Nature, 467, 1061–1073.
107. Pers, T.H., Karjalainen, J.M., Chan, Y., Westra, H.-J., Wood,
A.R., Yang, J., Lui, J.C., Vedantam, S., Gustafsson, S., Esko,
T. et al. (2015) Biological interpretation of genome-wide
association studies using predicted gene functions. Nat.
Commun., 6, 5890–5890.
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/28/15/2615/5439584 by H
ulib user on 15 N
ovem
ber 2019
